The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial

Davina J Tai, Kelvin Leung, Pietro Ravani, Robert R Quinn, Nairne Scott-Douglas, Jennifer M MacRae, Alberta Kidney Disease Network, Davina J Tai, Kelvin Leung, Pietro Ravani, Robert R Quinn, Nairne Scott-Douglas, Jennifer M MacRae, Alberta Kidney Disease Network

Abstract

Background: Unfractionated heparin is the most common anticoagulant used in haemodialysis (HD), although it has many potential adverse effects. Citrate dialysate (CD) has an anticoagulant effect which may allow reduction in cumulative heparin dose (CHD) compared to standard acetate dialysate (AD).

Methods: This double-blinded, randomised, cross-over trial of chronic haemodialysis patients determines if CD allows reduction in CHD during HD compared with AD. After enrolment, intradialytic heparin is minimised during a two-week run-in period using a standardised protocol based on a visual clotting score. Patients still requiring intradialytic heparin after the run-in period are randomised to two weeks of HD with AD followed by two weeks of CD (Sequence 1) or two weeks of HD with CD followed by two weeks of AD (Sequence 2). The primary outcome is the change in CHD with CD compared with AD. Secondary outcomes include metabolic and haemodynamic parameters, and dialysis adequacy.

Discussion: This randomised controlled trial will determine the impact of CD compared with AD on CHD during HD.

Trial registration: ClinicalTrials.gov NCT01466959.

Figures

Fig. 1
Fig. 1
Study Flow Diagram

References

    1. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11(2):178–189. doi: 10.1111/j.1542-4758.2007.00166.x.
    1. Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis. 2012;60(3):473–486. doi: 10.1053/j.ajkd.2012.03.017.
    1. Pawlak K, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol. 2004;24(1):154–161. doi: 10.1159/000076244.
    1. Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. Semin Dial. 2010;23(5):510–515. doi: 10.1111/j.1525-139X.2010.00770.x.
    1. Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis. 2008;51(5):789–795. doi: 10.1053/j.ajkd.2007.12.040.
    1. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int. 2003;64(4):1455–1461. doi: 10.1046/j.1523-1755.2003.00225.x.
    1. Chachati A, Godon JP. Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transplant. 1987;1(4):233–237.
    1. Yang JY, Lee TC, Montez-Rath ME, Paik J, Chertow GM, Desai M, Winkelmayer WC. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol. 2012;23(3):495–506. doi: 10.1681/ASN.2011070658.
    1. Seliger SL, Gillen DL, Longstreth WT, Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64(2):603–609. doi: 10.1046/j.1523-1755.2003.00101.x.
    1. Davenport A. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Am J Kidney Dis. 2009;54(2):361–374. doi: 10.1053/j.ajkd.2009.03.012.
    1. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest. 2003;63(1):45–53. doi: 10.1080/00365510310000484.
    1. Schulman S, Hellgren-Wangdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost. 2002;87(2):180–181.
    1. Binici DN, Gunes N. Risk factors leading to reduced bone mineral density in hemodialysis patients with metabolic syndrome. Ren Fail. 2010;32(4):469–474. doi: 10.3109/08860221003675260.
    1. Lai KN, Ho K, Cheung RC, Lit LC, Lee SK, Fung KS, Tong MK, Lam CW. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs. 2001;24(7):447–455.
    1. Edes TE. Heparin-induced hyperkalemia. Postgrad Med. 1990;87(4):104–106.
    1. Hottelart C, Achard JM, Moriniere P, Zoghbi F, Dieval J, Fournier A. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs. 1998;22(7):614–617. doi: 10.1046/j.1525-1594.1998.06204.x.
    1. Tu A, Ahmad S. Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant. 2000;29:620–626.
    1. Ahmad S, Callan R, Cole JJ, Blagg CR. Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis. 2000;35(3):493–499. doi: 10.1016/S0272-6386(00)70203-4.
    1. Ahmad S, Callan R, Cole J, Blagg C. Increased dialyzer reuse with citrate dialysate. Hemodial Int. 2005;9(3):264–267. doi: 10.1111/j.1492-7535.2005.01140.x.
    1. Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009;4(9):1459–1464. doi: 10.2215/CJN.02590409.
    1. Daimon S, Dan K, Kawano M. Comparison of acetate-free citrate hemodialysis and bicarbonate hemodialysis regarding the effect of intra-dialysis hypotension and post-dialysis malaise. Ther Apher Dial. 2011;15(5):460–465. doi: 10.1111/j.1744-9987.2011.00976.x.
    1. Kuragano T, Kida A, Furuta M, Yahiro M, Kitamura R, Otaki Y, Nonoguchi H, Matsumoto A, Nakanishi T. Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. Artif Organs. 2012;36(3):282–290. doi: 10.1111/j.1525-1594.2011.01349.x.
    1. Kuragano T, Furuta M, Yahiro M, Kida A, Otaki Y, Hasuike Y, Matsumoto A, Nakanishi T. Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH. BMC Nephrol. 2013;14:18-2369–14-18. doi: 10.1186/1471-2369-14-18.
    1. Aniort J, Petitclerc T, Creput C. Safe use of citric acid-based dialysate and heparin removal in postdilution online hemodiafiltration. Blood Purif. 2012;34(3–4):336–343. doi: 10.1159/000345342.
    1. Masuda A, Hagiwara S, Tanimoto M, Kodama F, Okumura K, Nohara N, Matsumoto M, Maiguma M, Omote K, Io H, Kurusu A, Ohsawa I, Shimizu Y, Hamada C, Horikoshi S, Tomino Y. Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients. Nephron Extra. 2012;2(1):256–268. doi: 10.1159/000342258.
    1. Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA. Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012;33(1–3):199–204. doi: 10.1159/000334157.
    1. Panichi V, Fiaccadori E, Rosati A, Fanelli R, Bernabini G, Scatena A, Pizzarelli F. Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients. ScientificWorld J. 2013;2013:703612. doi: 10.1155/2013/703612.
    1. Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M. Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid–base status, and electrolytes. BMC Nephrol. 2009;10:7-2369–10-7. doi: 10.1186/1471-2369-10-7.
    1. Stegmayr BG, Jonsson P, Mahmood D. A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation. Int J Artif Organs. 2013;36(1):1–6. doi: 10.5301/ijao.5000172.
    1. Kossman RJ, Callan R, Ahmad S. Fifty-five percent heparin reduction is sate with citrate dialysate in chronic dialysis patients [abstract]. American Society of Nephrology Annual Meeting 2006
    1. Saito T, Saito O, Maeda T, Ito C, Ando Y, Yamagata T, Muto S, Momoi M, Kusano E. Metabolic and hemodynamic advantages of an acetate-free citrate dialysate in a uremic case of congenital methylmalonic acidemia. Am J Kidney Dis. 2009;54(4):764–769. doi: 10.1053/j.ajkd.2009.04.033.
    1. Hanevold C, Lu S, Yonekawa K. Utility of citrate dialysate in management of acute kidney injury in children. Hemodial Int. 2010;14(Suppl 1):S2–6. doi: 10.1111/j.1542-4758.2010.00483.x.
    1. Winrow RM, Davis C, Halldorson JB, Ahmad S. Intraoperative dialysis during liver transplantation with citrate dialysate. Hemodial Int. 2009;13(3):257–260. doi: 10.1111/j.1542-4758.2009.00370.x.
    1. Sagedal S, Hartmann A, Osnes K, Bjornsen S, Torremocha J, Fauchald P, Kofstad J, Brosstad F. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant. 2006;21(2):444–449. doi: 10.1093/ndt/gfi203.
    1. Krivitski NM, Kislukhin VV, Snyder JW, MacGibbon DR, Kuznetsova OA, Reasons AM, Depner TA. In vivo measurement of hemodialyzer fiber bundle volume: theory and validation. Kidney Int. 1998;54(5):1751–1758. doi: 10.1046/j.1523-1755.1998.00146.x.
    1. Manns BJ, Mortis GP, Taub KJ, McLaughlin K, Donaldson C, Ghali WA. The Southern Alberta Renal Program database: a prototype for patient management and research initiatives. Clin Invest Med. 2001;24(4):164–170.
    1. Petitclerc T, Goux N, Reynier AL, Bene B. A model for non-invasive estimation of in vivo dialyzer performances and patient’s conductivity during hemodialysis. Int J Artif Organs. 1993;16(8):585–591.
    1. Kuhlmann U, Goldau R, Samadi N, Graf T, Gross M, Orlandini G, Lange H. Accuracy and safety of online clearance monitoring based on conductivity variation. Nephrol Dial Transplant. 2001;16(5):1053–1058. doi: 10.1093/ndt/16.5.1053.
    1. Ahmad S, Callan R, Kossman R. Heparin reduction with citrate dialysate [abstract]. Nephrol Dial Transplant 2006; 21:suppl.4.
    1. Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91–92. doi: 10.1016/S0140-6736(12)62160-6.
    1. Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672–677. doi: 10.1016/j.ijsu.2011.09.004.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner